Objective. To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA.
Introduction
RA is a chronic auto-immune disease affecting 1% of the adult population and is characterized by joint inflammation and bone erosions [1] . The primary aim in the treatment of RA is to alleviate symptoms, preserve physical function and improve health-related quality of life (HRQoL) by reducing disease activity. Patient-reported outcomes (PROs) are considered crucial when evaluating new therapies in clinical trials as they reflect the effectiveness and tolerability from the patients' perspective [24] . Together with physician-reported assessments, laboratory, and imaging results, these measures provide a comprehensive insight into the overall treatment effect [5, 6] . The patients' reported well-being is also important in the management of RA as a tool for shared decision-making and a variety of PROs are available to monitor health domains such as pain, physical function, psychosocial impact, HRQoL and disease activity [2] . The OMERACT international initiative has developed a core outcome set that is strongly advocated to be used in studies within RA patients, to evaluate these domains [4] .
Tocilizumab, an IL-6 receptor-inhibiting antibody, is a treatment option for RA and has demonstrated a rapid reduction of disease activity and an acceptable safety profile across several phase III studies [718] . In the U-Act-Early strategy trial (ClinicalTrials.gov identifier NCT01034137), DMARD-naïve patients with active early RA were enrolled from 21 participating hospitals and treated with step-up MTX, tocilizumab or tocilizumab plus MTX therapy. Results of this study demonstrated that initiation of tocilizumab therapy, with or without MTX, was more efficacious when compared with initiating MTX alone. Primary efficacy data have been reported recently [19] . The present study evaluated the effect of the three treat-to-target strategies on PROs, and whether more improvement in PROs was associated with adequate targeting of the inflammation.
Methods
Study design and population U-Act-Early was a 2-year, multicentre, three-parallel-arm, double-blind, treat-to-target strategy trial including adult DMARD-naïve patients (>18 years old) who met the 1987/ 2010 classification criteria [20, 21] , had active disease (DAS28 >2.6), and had been diagnosed with RA within the previous year. Patients were randomized (1:1:1) to initiate MTX, tocilizumab or tocilizumab plus MTX and treated in a step-up method until the treatment target, sustained remission (defined as DAS28 <2.6 and 44 swollen joints for 524 weeks), was achieved. Tocilizumab (8 mg/kg) was given intravenously every 4 weeks up to a maximum of 800 mg/dose. MTX (orally) was started at 10 mg/week and increased to 30 mg/week with 5 mg every 4 weeks until remission or maximum tolerable dose was reached and patients received folic acid 5 mg twice per week to reduce MTX-related toxicity. When sustained remission was achieved, medication was tapered stepwise and stopped, if remission persisted. First, MTX was tapered with 5 mg every 4 weeks until 10 mg and then stopped, followed by tocilizumab, which was decreased to monthly 4 mg/kg for 3 months and then stopped. A more detailed description of the treatment strategies has been reported previously [19] .
PROs
All PROs were pre-defined as secondary endpoints and were assessed at baseline and after 12, 24, 52 and 104 weeks. Fatigue was measured by the 13-item Functional Assessment of Chronic Illness TherapyFatigue (FACIT-F) questionnaire with scores ranging from 0 to 52 where higher scores indicate less severe fatigue. The 36-item Short Form (SF-36), comprising eight different domains (physical functioning, role physical, bodily pain, general health, vitality, social function, role emotional and mental health) [22, 23] , and the five-dimensional EuroQol (EQ-5D) were used to measure the HRQoL [24] . For each domain in the SF-36, item scores were transformed to a scale from 0 (i.e. worst possible health state) to 100 (i.e. best possible health state). Subsequently, these domains were combined to calculate the physical (SF-36 PCS) and mental (SF-36 MCS) component scores (range 0100). The EQ-5D has five dimensions (mobility, self-care, usual activity, pain/discomfort and anxiety/depression), which can be scored as 0 (no problem), 1 (some problems) or 2 (severe problems). These categorical responses were transformed into utility scores anchored by 01, with 1 indicating perfect health. In addition, we also evaluated the second part of the EQ-5D questionnaire containing a visual analogue scale (EQ-VAS) where patients could score their general health on a range from 0 (i.e. the worst health state you can imagine) to 100 (i.e. the best health state you can imagine). Illness beliefs was measured with the Revised Illness Perception Questionaire (IPQ-R) [25, 26] , comprising nine different scales (identity, timeline, consequences, personal control, treatment control, illness coherence, timeline cyclical, emotional representations and cause), with higher scores indicating a worse perception of illness. The domain cause was not considered for analysis as it contains no quantitative data. Minimum clinically important differences (MCID), which can be considered as the smallest change in an outcome that a patient would identify as important, were achieved if patients exceeded the following thresholds for increase from baseline: 52.5-point increase in SF-36 PCS or MCS and 55-point increase for SF-36 domain scores [27] ; 50.05-point increase in EQ-5D score [28] ; 58-point increase in EQ-VAS score [29] ; and 54-points increase in FACIT-F score [30] . No MCID has been defined for IPQ-R.
Statistical analyses
Patients who were randomized and received at least one dose of medication were included in the analysis (intention-to-treat population). Baseline characteristics are described by mean (S.D.) or median and interquartile range (IQR), depending on the distribution of the data.
Binary outcomes were presented as proportions. We used a linear mixed model to evaluate between-group differences in PRO scores over time with a random intercept and week of visit, strategy arm, baseline questionnaire score, baseline DAS28 (i.e. DAS28 <5.1 or 55.1) and centre as fixed effects. For between-group comparisons of scores at specific time points we used a one-way ANCOVA, adjusted for baseline questionnaire score, baseline DAS28 and centre. The proportions of patients achieving MCID were compared between the strategy arms per time point using a two-sided Pearson's chisquared test. To evaluate if PROs were associated with inflammation, we compared the levels of CRP and ESR over time between those achieving MCID and those who did not achieve it using a logistic mixed effect model (using a random intercept; week of visit and strategy arm as well as ESR or CRP as fixed effects) and achieving MCID (yes vs no) as dependent variable. Furthermore, we subsequently evaluated if the association between acute phase reactants (APRs) and PROs, expressed in odds ratios (ORs), was independent from clinical signs of disease activity related to this inflammation, by correcting for tender and swollen counts assessing 28 joints. ESR and CRP as well the clinical disease activity parameters were log transformed and then standardized (z scores) for better comparison of the regression coefficients. Finally, to evaluate the accordance between patient-reported and clinical improvements, we compared the proportion of patients achieving DAS28 remission (<2.6) within those reporting MCID. No imputation for missing data was applied and no correction for multiple testing was performed. Statistical significance was set at P < 0.05 (two tailed) and analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results

Patients
In total, 317 patients were randomized: 108 to the MTX strategy, 103 to the tocilizumab strategy and 106 to the tocilizumab plus MTX strategy. Of these, 78 (72%), 81 (79%) and 78 (74%) completed the 2-year follow-up, respectively. Baseline characteristics were similar between the strategy arms: 6176% female, median symptom duration 2527 days and the majority had seropositive disease (6680% seropositive for RF, 6578% seropositive for CCP; Table 1 ). Baseline PRO scores were comparable (P 5 0.31) across the strategy arms with values indicating relatively severe impairments from the patients' perspective (Table 2 ).
FACIT-F
Although patients starting with tocilizumab-based strategies reported greater improvements in fatigue during the 2-year study period compared with the MTX strategy, when performing a linear mixed effect model there were no significant differences over time between tocilizumab (P = 0.052) and tocilizumab plus MTX (P = 0.16) vs MTX alone (Table 2 ). There were however significant differences in favour of tocilizumab at week 12 (tocilizumab vs MTX, P = 0.023) and week 24 (tocilizumab vs MTX, P = 0.038; tocilizumab plus MTX vs MTX, P = 0.038; Fig. 1 ). Proportions of patients achieving MCID were not significantly different between both tocilizumab arms vs the MTX arm (P 5 0.19; Fig. 2 ) during follow-up.
SF-36
We found significantly greater improvements in the SF-36 PCS in patients treated with tocilizumab than in those treated with MTX (tocilizumab vs MTX, P = 0.044; tocilizumab plus MTX vs MTX, P = 0.012; Fig.1 and Table 2 ). In addition, a significantly higher proportion of patients treated with tocilizumab achieved MCID in the SF-36 PCS at week 12 (tocilizumab vs MTX, P = 0.016; tocilizumab plus MTX vs MTX, P = 0.049) and week 52 (tocilizumab vs MTX, P = 0.030; tocilizumab plus MTX vs MTX, P = 0.027; Fig. 2 ). For the SF-36 MCS, no significant differences in scores were noted over time between the strategy arms (P 5 0.13). Only at 24 weeks, there was a significant difference in the SF-36 MCS between the tocilizumab plus MTX arm and the MTX arm (P = 0.034). No significant differences were found between the strategy arms in the proportions of patients achieving MCID in the SF-36 MCS at follow-up (P 5 0.06). When evaluating the domains of the SF-36 separately, a pattern similar to that of the PCS and MCS was noted in which greater improvements were found predominantly during the first 24 weeks of the study in both tocilizumab strategies, when compared with the MTX strategy (supplementary Fig. S1 , available at Rheumatology Online). These differences were mainly found in domains related to physical health and less in domains related to mental health. 
EQ-5D and EQ-VAS
Patients who initiated treatment with tocilizumab, with or without MTX, showed greater improvements in HRQoL when compared with those initiating MTX alone. During the study, significant higher EQ-5D scores were found in the tocilizumab plus MTX strategy when compared with the MTX strategy (P = 0.020; Table 2 ). The difference between the tocilizumab and MTX strategy was not significantly different (P = 0.09). When comparing the strategy arms at the different time points, significant differences were found between the tocilizumab strategies and the MTX strategy in EQ-5D scores at week 12 (tocilizumab vs MTX, P = 0.009; tocilizumab plus MTX vs MTX, P = 0.041) and week 24 (tocilizumab plus MTX vs MTX, P = 0.003). At weeks 52 and 104 there were no significant differences between the strategy arms (P 5 0.33). Furthermore, the proportion of patients achieving MCID was only at week 24 significantly higher in the tocilizumab plus MTX strategy when compared with the MTX strategy (P = 0.045; Fig. 2 ). In EQ-VAS scores, no significant differences were found over time between the tocilizumab strategies and the MTX strategy (tocilizumab plus MTX, P = 0.14; tocilizumab, P = 0.17) and neither the proportions of patients achieving MCID statistically differed (P 5 0.06) between the treatment strategies. Only at week 12 were EQ-VAS scores significant higher in the tocilizumab plus MTX and tocilizumab strategy when compared with the MTX strategy (P = 0.001 and P = 0.039, respectively).
IPQ-R
Baseline IPQ-R scores and improvements from baseline are shown in the supplementary Table S1 , available at Rheumatology Online. We found no statistically significant differences between the tocilizumab arms and the MTX arm, except for the dimension Identity (tocilizumab vs MTX, P = 0.048) where scores were significantly lower in favour of the tocilizumab strategy. Overall, we found only minor changes over time within the groups in IPQ-R scores, indicating a low effect of the treatment strategies on the perception of illness beliefs.
Association of acute phase reactants with PROs
To evaluate if patients who achieved MCID in PROs also have lower concentrations of APRs, we compared the levels of CRP and ESR between those achieving MCID and those who did not achieved it within each strategy arm (Fig. 3) . For all PROs, we found lower levels of APRs in those reporting clinically relevant improvements and although both inflammatory markers have different half-lives, similar patterns were seen between both reactants. In addition, we analysed if clinical disease activity, measured by swollen and tender joint counts, was associated with APRs and PROs and thus may be considered as a confounder in the relationship between inflammation and the patients' well-being. The ORs for achieving MCID are shown in Table 3 . Results show that higher levels of APRs decreased the chance of achieving MCID and that after correction for the effect of swollen and tender joint counts the ORs generally decreased toward 1, indicating that the association between PROs and APRs was indeed confounded by clinical symptoms and signs. Furthermore, the crude ORs for joint counts were overall lower than those for APRs suggesting a more important influence on PROs and also indicating that higher joint counts were related to a lower chance of achieving MCID (results not shown).
Patient-reported vs clinical improvements
The cumulative numbers of patients achieving MCID in PROs and clinical remission (DAS28 < 2.6) are shown in supplementary -5D ; (E) EQ-VAS. P-values calculated using a logistic (achieving MCID vs not achieving MCID) mixed model to evaluate group differences over time within each treatment arm with a random intercept and week of visit and change from baseline (Á) in ESR or CRP as fixed effects. Patients could switch between different time points in achieving MCID or not. *P < 0.05; **P < 0.01; ***P < 0.001. EQ-5D: five dimensional EuroQol; FACIT-Fatigue: functional assessment of chronic illness therapy-fatigue; ITT: intention-to-treat; MCID: minimally clinically important differences; MCS: mental component score; PCS: physical component score; S.E.: standard error; SF-36: short-form 36-item survey; TCZ: tocilizumab; VAS: visual analogue scale.
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Discussion
In our strategy trial within early DMARD-naive RA patients, better clinical outcomes and acceptable safety profiles were shown when initiating treat-to-target tocilizumab therapy, with or without MTX, compared with initiation of MTX therapy alone [19] . The findings of this study are in line with the clinical efficacy data, since both tocilizumab strategies resulted in significantly and clinically relevant improvements in PROs compared with the MTX strategy. These PROs consisted of a number of questionnaires reflecting the patients' perception on several health domains. Patients who initiated a tocilizumab-based strategy showed overall greater and more rapid improvements, especially within the first 24 weeks, compared with those in the MTX strategy. However, in the illness beliefs as measured by the IPQ-R, no distinct differences over time could be noted between the strategies, probably because of the relatively low baseline scores in this questionnaire. This may be explained by the fact that only newly diagnosed patients were included in the study; patients with established RA are more likely to develop negative beliefs about their illness and a passive coping style, negatively influencing the treatment effect [31] . Furthermore, we evaluated if inflammation was directly associated with the patients' self-reported well-being by comparing the level of APRs between those achieving MCID and those not achieving it. Although we found that a higher level of APRs decreased the chance of achieving MCID, after correcting for joints counts a less strong association was noted showing that patients reporting greater improvements probably experienced fewer clinical symptoms. The patient-reported improvements were also largely in agreement with improvements seen in clinical outcomes; the majority of those who achieved MCID during follow-up also achieved remission (74%), confirming the accordance between PROs and level of disease activity. To our knowledge, so far only one randomized controlled trial evaluated the effect of tocilizumab on fatigue in RA patients; in that study, patients were treated with tocilizumab (4 or 8 mg/kg) plus MTX or MTX therapy alone [32] . Within the first 24 weeks of treatment, significant higher FACIT-F scores were found in those treated with the higher dose of tocilizumab when compared with those who received MTX therapy (P = 0.015). In the same study, they also evaluated the SF-36 questionnaire and reported Although we were not able in our study to demonstrate significant differences in fatigue between the tocilizumab strategies and the MTX strategy when analysing the 2-year study as a whole (because eventually all three strategy groups achieved similar efficacy based on the treat-to-target design), we did find significant differences within the first 24 weeks of the study in favour of the tocilizumab strategies, which supports the findings of the previous study. Another tocilizumab study also reported on SF-36 scores where significant differences (P 4 0.007) were found during follow-up (weeks 24 and 52) in the PCS when comparing tocilizumab plus MTX vs MTX [12] . No differences in the PCS were noted in that study between the tocilizumab and MTX arm or between the three treatment arms in the MCS. These findings are overall in agreement with our study, except that we found significant differences between the tocilizumab vs MTX arm in the PCS at weeks 12 and 52 (P 4 0.014). Our study has some limitations that need to be addressed. Although this is the first study reporting 2-year effects of tocilizumab on PROs in DMARD-naïve patients with early RA, assessments were only performed four times during follow-up whereas previous similar studies evaluating different DMARDs assessed PROs more often and thus are more sensitive for detecting short-term transitions in health status [33, 34] . Furthermore, this is the first study in which DMARD-naïve RA patients were treated with tocilizumab as initial therapy, that is, without receiving prior conventional synthetic DMARDs. Although this is not in agreement with current international guidelines [2, 3] , starting therapy with tocilizumab may improve the longterm clinical outcome by effectively targeting the inflammation rapidly. However, a proportion of patients would then possibly be over-treated as they might also have achieved remission on the less expensive conventional synthetic DMARDs. Further research regarding the costeffectiveness and long-term safety of initiating a tocilizumab-based strategy in newly diagonised RA patients is necessary.
In general, a high response was noted in this study in those who initiated MTX therapy compared with other tocilizumab studies with an MTX comparator arm. In previous studies, patients were already on a stable dose of MTX before inclusion and despite an inadequate response continued MTX as therapy [7, 8, 10, 16, 18] . Continuing treatment that is ineffective underestimates the potential efficacy of MTX causing distorted results when effects are compared with those of tocilizumab therapy. The exceptions are the AMBITION study, where 67% of patients, and the FUNCTION study, where all patients who were assigned to initiate MTX therapy were MTX-naïve [12, 17] . However, in these studies patients were not entirely DMARD-naïve and thus treatment response could still have been affected. Furthermore, in our study tocilizumab could be added if MTX did not lead to remission; this was actually the case in 46% (50/108) of the patients in the MTX strategy arm. These patients were included in the PRO analyses of our study when evaluating the efficacy of MTX step-up therapy as adding tocilizumab was part of the treatment strategy.
In conclusion, in this study among DMARD-naïve patients with early RA, initiating a treat-to-target tocilizumab-based strategy resulted in significantly higher and clinically relevantly more improvements in PRO scores when compared with initiation of an MTX-based strategy. Especially within the first 24 weeks, greater improvements were noted in the tocilizumab strategies when compared with the step-up MTX strategy, which may be crucial for patients when resuming work-related activities. In those reporting more improvements in PROs, significantly lower levels of APRs were found, indicating more adequate targeting of the disease within these patients, causing less impairments and therefore a better well-being from the patients' perspective. Eventually, the differences in Units of acute phase reactants expressed in S.D. Odds ratios were calculated using a logistic (achieving MCID vs not achieving MCID) mixed model to evaluate between-group differences over time with a random intercept and time (visit week) and ESR or CRP as fixed effects. In the corrected model, SJC28 and TJC28 was added as fixed effects. Disease activity variables (ESR, CRP, TJC28 and SJC28) were log transformed and then standardized (z scores) to calculate the regression coefficients.
a Odds ratio corrected for SJC28 and TJC28. * P < 0.05; ** P < 0.01; *** P < 0.001. EQ-5D: five dimensional EuroQol; FACIT-F: functional assessment of chronic illness therapy-fatigue; MCID: minimally clinically important differences; MCS: mental component score; OR: odds ratio; PCS: physical component score; PRO: patient-reported outcomes; SF-36: short-form 36-item survey; SJC28: swollen joint count assessing 28 joints; TJC28: tender joint count assessing 28 joints; VAS: visual analogue scale.
www.rheumatology.oxfordjournals.org PROs between the treatment arms during follow-up did decreased as U-Act-Early was a treat-to-target strategy trial, in which medication was adjusted if patients failed to achieve sustained remission. However, the more favourable initial results in the tocilizumab strategies are nevertheless important, also for the long-term outcome, as not only did a higher proportion of patients manage to achieve drug-free remission but also the progression of radiographic changes was significantly lower in the tocilizumab arms when compared with the MTX arm. The findings of the present study support the previously reported clinical efficacy and safety data and suggest that tocilizumab may be a valuable first line of therapy in newly diagnosed RA patients.
